IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress

December 13, 2018 04:05 ET | Source: IMV Inc. 73% of tumor regressions and 80% of clinical responses were observed in a subpopulation defined by a clinical biomarker based on Baseline Tumor Burden ...